B. Riley analyst Madison El-Saadi initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $179 price target The firm believes a window is open for entry ahead of Q3 earnings, a second wave of potential 2026 approvals, and initiation of a third wave of late-stage candidates in Q4, the analyst tells investors in a research note. Axsome’s late-stage pipeline includes multiple hidden low-hanging opportunities not currently in the firm’s model, B. Riley says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics initiated with a Buy at B. Riley
- Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
- RBC lists biotech winners should RFK depart HHS
- RBC lists biotech winners should RFK departure HHS
- Axsome Therapeutics assumed with an Overweight at Wells Fargo